Haifaa Abdulhaq, MD

Clinical Professor of Medicine
Medicine - Fresno
+1 559 499-6500

Haifaa Abdulhaq, M.D.
Clinical Professor, UCSF

Haifaa Abdulhaq, M.D. is Clinical Professor in Hematology and Oncology, UCSF and she is the director of hematology at UCSF Fresno and the director of Hematology/Oncology fellowship program at UCSF Fresno. She is board certified in hematology and medical oncology with expertise in Malignant Hematology including Lymphoproliferative neoplasms, Myeloproliferative neoplasms, Acute Leukemia, Multiple Myeloma and interest in Stem Cell transplantation.

Dr. Abdulhaq completed her residency in internal medicine and fellowship in hematology & oncology at Western Pennsylvania Hospital and Allegheny General Hospital in Pittsburgh, Pennsylvania.

She is a member of The American Society of Hematology, the American Board of Internal Medicine, the American Society of Clinical Oncology and the American Society of Blood and Bone Marrow Transplantation. Dr. Abdulhaq is a board member of the Leukemia and Lymphoma Society, Central California Chapter and she also serves as the chair of Cancer Committee at Community Medical Centers.

Dr. Abdulhaq has special interest in medical education. She is a recipient of Henry Kaiser Award for Excellence in teaching at UCSF . She is also interested in clinical research and serves as the principal investigator on many clinical trials in malignant hematology.

Publications

ABCL-544: Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): 2 Year Follow-Up of the Phase 3 STARGLO Trial.

Clinical Lymphoma Myeloma & Leukemia

Jeremy S. Abramson, Matthew Ku, Mark Hertzberg, Christopher P. Fox, Charles Herbaux, Hui-Qiang Huang, Dok Hyun Yoon, Won Seog Kim, Huilai Zhang, Haifaa Abdulhaq, William Townsend, Estefania Mulvihill, Victor Orellana-Noia, Richard Ta, Huang Huang, Martine Joanna Kallemeijn, Anton Belousov, Alessia Bottos, Linda Lundberg, Gareth P. Gregory

POSTER: ABCL-544 Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): 2 Year Follow-Up of the Phase 3 STARGLO Trial.

Clinical Lymphoma Myeloma & Leukemia

Jeremy S. Abramson, Matthew Ku, Mark Hertzberg, Christopher P. Fox, Charles Herbaux, Hui-Qiang Huang, Dok Hyun Yoon, Won Seog Kim, Huilai Zhang, Haifaa Abdulhaq, William Townsend, Estefania Mulvihill, Victor Orellana-Noia, Richard Ta, Huang Huang, Martine Joanna Kallemeijn, Anton Belousov, Alessia Bottos, Linda Lundberg, Gareth P. Gregory

Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO.

Journal of Clinical Oncology

Jeremy S. Abramson, Matthew Ku, Mark Hertzberg, Christopher P. Fox, Charles Herbaux, Dok Hyun Yoon, Won Seog Kim, Huilai Zhang, Haifaa Abdulhaq, William Townsend, Estefania Mulvihill, Victor Orellana-Noia, Richard Ta, Huang Huang, Martine Kallemeijn, Anton Belousov, Alessia Bottos, Linda Lundberg, Gareth P. Gregory

Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study.

Blood

Gareth P. Gregory, Jeremy S. Abramson, Hui-Qiang Huang, Qing-Yuan Zhang, Matthew Ku, Dok Hyun Yoon, Christopher P. Fox, Haifaa Abdulhaq, William Townsend, Joan Ashby, Alana Harris, Victor Orellana-Noia, Stephen Simko, Martine Kallemeijn, Richard Ta, James Relf, Huang Huang, Linda Lundberg, Huilai Zhang